Evidence map›Paper›PMID 41844661›Full record

ArticleScientific reports2026

Magnetic BiFeO

Safa Hanifi, Mohammad G Dekamin, Mohammad Eslami

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Safa HanifiPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846‑13114, Iran.
Mohammad G DekaminPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846‑13114, Iran. mdekamin@iust.ac.ir.
Mohammad EslamiDepartment of Chemistry, Behbahan Khatam Alanbia University of Technology, Behbahan, 63616‑63973, Iran.

Funding

Iran University of Science and Technology 160/25285
6 · The paper itself

Abstract

This study reports the use of magnetic bismuth ferrite, BiFeO₃, nanoparticles (BFO MNPs), as a robust and eco-friendly catalyst, for the one-pot, mild synthesis of highly substituted imidazole derivatives under solvent-free conditions, thus avoiding toxic organic solvents. The approach offers several advantages, including short reaction times, low catalyst loading, and consistently high to excellent yields with broad applicability across diverse imidazole derivatives. Furthermore, the BiFeO₃ nanocatalyst demonstrated excellent recyclability and stability, maintaining its catalytic performance over five consecutive cycles without any significant loss in its activity, thereby enabling sustainable and scalable applications. The structural and morphological properties of the synthesized BiFeO₃ nanocatalyst were thoroughly characterized using Fourier-transform infrared (FT-IR) spectroscopy, scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), EDS elemental mapping, X-ray diffraction (XRD), vibrating sample magnetometry (VSM), and Brunauer–Emmett–Teller (BET) surface area analysis. Additionally, the structures of the synthesized imidazole derivatives were confirmed by 1H NMR spectroscopy, FT-IR analysis, and melting point determination. Overall, this study highlights the potential of BiFeO₃ nanoparticles as a sustainable, high-performing, and environmentally benign catalyst, making a meaningful contribution to the advancement of green chemistry and innovative synthetic methodologies.

Indexed as

BFO nanoparticlesBiFeO3Bismuth ferriteGreen and sustainable chemistryImidazole derivativesMagnetic catalystMulti-Component Reactions (MCRs)Nanocatalyst

Identifiers

PMID41844661
PMCPMC13035956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.